Geneos Therapeutics to Present New Clinical Data on GNOS-PV02 at the 2024 American Association for Cancer Research (AACR) Annual Meeting

Rhea-AI Summary

Geneos Therapeutics announces the presentation of new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, at the 2024 AACR Annual Meeting. The data includes the use of GNOS-PV02 in combination with pembrolizumab for advanced hepatocellular carcinoma patients.

PHILADELPHIA, March 6, 2024 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of personalized therapeutic cancer vaccines (PTCV), today announced the upcoming presentation of two posters sharing new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, in patients with advanced hepatocellular carcinoma, at the 2024 American Association for Cancer Research (AACR) Annual Meeting. The AACR Annual Meeting will be held in San Diego from April 5-10.

Details of the poster presentations are as follows:

Title: Personalized neoantigen DNA vaccine GNOS-PV02 and pembrolizumab as second-line treatment for advanced hepatocellular carcinoma
Presenting Author: Mark Yarchoan, MD
Abstract Number: 1191
Poster Board Number: 25
Session Title: Tumor Immune Response 1
Session Date and Time: Sunday, Apr 7, 2024, 1:30 pm - 5:00 pm PT
Location: San Diego Convention Center, Poster Section 47

Title: Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune checkpoint blockade
Presenting Author: Jian Yan, PhD
Abstract Number: 976
Poster Board Number: 17
Session Title: Circulating Nucleic Acids 1
Session Date and Time: Sunday, April 7, 2024, 1:30 pm - 5:00 pm PT
Location: San Diego Convention Center, Poster Section 40

About Geneos Therapeutics
Geneos Therapeutics, a clinical stage biotherapeutics company, is developing personalized therapeutic cancer vaccines (PTCVs) that may serve an important role in new immunotherapeutic paradigms for cancer. The company's approach, using its proprietary GT-EPIC™ platform, is to target neoantigens (abnormal mutations produced by cancer cells) from individual patient tumors to develop novel and uniquely personalized treatments for cancer. Planning is underway for a potentially registrational clinical trial in advanced hepatocellular carcinoma. For more information, please visit www.geneostx.com.

View original content:https://www.prnewswire.com/news-releases/geneos-therapeutics-to-present-new-clinical-data-on-gnos-pv02-at-the-2024-american-association-for-cancer-research-aacr-annual-meeting-302080667.html

SOURCE Geneos Therapeutics, Inc.

FAQ

What is Geneos Therapeutics presenting at the 2024 AACR Annual Meeting?

Geneos Therapeutics is presenting new clinical data from its Phase 1b/2a GT-30 study of GNOS-PV02, a personalized neoantigen DNA vaccine, at the 2024 AACR Annual Meeting.

What is the focus of the clinical data being presented by Geneos Therapeutics?

The clinical data focuses on the use of GNOS-PV02 in combination with pembrolizumab as a second-line treatment for advanced hepatocellular carcinoma.

Who are the presenting authors of the posters at the AACR Annual Meeting?

Mark Yarchoan, MD, and Jian Yan, PhD are the presenting authors of the posters at the AACR Annual Meeting.

When and where will the poster presentations take place?

The poster presentations will take place on Sunday, April 7, 2024, from 1:30 pm to 5:00 pm PT at the San Diego Convention Center.

What is the abstract number for Mark Yarchoan's poster?

The abstract number for Mark Yarchoan's poster is 1191.

What is the abstract number for Jian Yan's poster?

The abstract number for Jian Yan's poster is 976.